Thyroid Eye Disease
Conditions
Keywords
Kamuvudine-9, K9
Brief summary
The study is comprised of two cohorts. Cohort 1 will examine pharmacokinetics of K9 in 3 healthy volunteers over 24 hours. This cohort has been completed. Cohort 2 will involve up to 10 patients with TED. Patients will receive oral K9 BID for up to 24 weeks and will be followed up to a total of 26 weeks with a primary endpoint of safety.
Interventions
DRUGKamuvudine-9
96 mg tablets taken twice a day for 24 weeks
Sponsors
Peter Timoney
Inflammasome Therapeutics
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Cohort 1 * Subject is willing and able to receive treatment and complete corresponding assessments as required by the protocol Cohort 2 * Diagnosed with Thyroid Eye Disease (TED). * Symptomatic TED diagnosed no more than 9 months earlier. * Clinical Activity Score ≥ 3 (on 7 point scale) for the worse eye. * Subject is willing and able to receive treatment and complete corresponding assessments as required by the protocol.
Exclusion criteria
Cohort 1 * Body weight less than 55 kg. * History of any clinically significant medical disorders the principal investigator considers exclusionary, including (but not limited to), neuromuscular, hematological disease, immune deficiency state, respiratory disease, hepatic or gastrointestinal disease, neurological or psychiatric disease, ophthalmological disorders, neoplastic disease, renal or urinary tract diseases, or dermatological disease. * Females who are pregnant, nursing, planning a pregnancy or who are of childbearing potential not using a reliable method of contraception. * History or current evidence of hypersensitivity to any components of the study medication, as assessed by the investigator. * Participation in any systemic experimental treatment or any other systemic investigational new drug within 6 weeks or 5 half-lives of the active ingredient (whichever is longer) prior to the start of study treatment. Clinical trials solely involving observation, over-the-counter vitamins, supplements, or diets are not exclusionary Cohort 2 * Body weight less than 55 kg. * Females who are pregnant, nursing, planning a pregnancy or who are of childbearing potential not using a reliable method of contraception. * History or current evidence of hypersensitivity to any components of the study medication, as assessed by the investigator. * Participation in any investigational drug or ocular device study within 30 days prior to the Day 1 Study Visit. * History or current evidence of a medical condition that may, in the opinion of the investigator, preclude the safe administration of study medication or affect the results of the study. * Participation in any systemic experimental treatment or any other systemic investigational new drug within 5 half-lives of the active ingredient prior to the start of study treatment. Clinical trials solely involving observation, over-the-counter vitamins, supplements, or diets are not exclusionary. * History of use of teprotumumab (Tepezza), radiotherapy, or orbital surgery. * History (last 6 weeks) of use of systemic immunosuppressants (e.g. mycophenolate), intravenous immunoglobulin, or plasmapheresis. * Clinical activity score \< 3 * Uncontrolled diabetes or hypertension * History of mental / psychiatric disorder * Hepatic dysfunction (Albumin (Alb), Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline phosphates levels must be within normal range for eligibility) * Renal impairment (Urea, Creatinine, and Glomerular Filtration Rate levels must be within normal range) * Any baseline condition that the principal investigator considers exclusionary.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Events | 26 weeks | Frequency of participants experiencing ocular or systemic adverse events. |
| plasma concentrations of K9 | Pharmacokinetic samples collected pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, and 24 hours after dosing | plasma concentrations measured after a single oral dose in healthy adults. For each of these time points 5 ml of blood will be drawn. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Standardized Patient Evaluation of Eye Dryness (SPEED) symptoms | Screening (Baseline), and Weeks 4, 14, and 24 | The SPEED Questionnaire will be used to track progression of dry eye symptoms. The SPEED questionnaire has eight questions. The frequency and severity of symptoms are rated on a numeric scale. Scores range from 0 to 28 with higher scores equating to more symptoms. |
| Change in Diplopia | Screening (Baseline), Day 1 Visit, and weeks 4, 14, and 24 | Diplopia is assessed by the Bahn-Gorman Scale. The Bahn-Gorman scale is a subjective grading scheme that uses a scale of 0-3 to assess the severity of diplopia. A higher score equates to more severe diplopia. |
| Change in Study Visit in Clinical Activity Score (CAS), | Screening (Baseline), Day 1 Visit, and weeks 4, 14, and 24 | Clinical Activity Score (7 point scale) with higher score equating to more symptoms |
| Change in proptosis | Screening (Baseline), Day 1 Visit, and weeks 4, 14, and 24 | Hertel exophthalmometry will be used to measure the globe position of the eye by calculating the distance from the lateral orbital rim to the surface of the cornea in millimeters (mm) |
| Change in Graves' ophthalmopathy-specific quality-of-life scale (GO-QOL) | Screening (Baseline) and weeks 4, 14, and 24 | The GO-QOL is a self-administered health-related QOL questionnaire specifically designed and validated in patients with TED. It includes 2 subscale GO-QOL scores: (1) visual functioning and (2) appearance-related, with the 2 weighted equally to create an overall score. Both the subscales and overall score are transformed to a scale of 0 to 100, 0 indicating worst health and 100 indicating best health. |
| Change in upper eyelid retraction | Screening (Baseline), Day 1 Visit, and weeks 4, 14, and 24 | upper eyelid retraction will be determined by measuring the margin reflex distance (MRD1) in millimeters. The MRD1 is the measurement in millimetres from the light reflex on the patient's cornea to the level of the centre of the upper eyelid margin, with the patient gazing in the primary position. |
| Change in lower eyelid retraction | Screening (Baseline), Day 1 Visit, and weeks 4, 14, and 24 | Lower eyelid retraction is measured by the distance from the inferior limbus to the lower eyelid, or by the margin reflex distance 2 (MRD2). The distance between the corneal light reflex to the central portion of the lower eyelid is measured in millimeters |
| Change in cell-based functional assays | Screening (Baseline), Day 1 Visit, and weeks 4,14, and 24 | measured by ELISA |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORPeter Timoney
University of Kentucky
Outcome results
None listed